PRIME-MD / PHQ Clinical Screening Framework
Spitzer, R. L., Kroenke, K. & Williams, J. B. W. · 1999
也被称为: PRIME-MD · PHQ Framework
The PHQ family descends from the Primary Care Evaluation of Mental Disorders and applies a single design principle: map each questionnaire item directly onto a diagnostic criterion, so that a non-specialist can administer it and a positive screen points to a specific follow-up rather than to generalised concern. The PHQ-9 covers the nine DSM criteria for major depressive episode over the last two weeks; the PHQ-2 is its two-item first stage; the PHQ-15 covers somatic symptom burden. These are screening instruments with published sensitivity and specificity — they identify who warrants assessment, and they do not diagnose.
Clinical screening framework derived from the Primary Care Evaluation of Mental Disorders (PRIME-MD). Operationalizes DSM-IV diagnostic criteria into brief self-report screeners for depression (PHQ-9/PHQ-2), anxiety (GAD-7), somatization (PHQ-15), and other conditions. Not a diagnostic system — designed to identify probable cases for clinical follow-up.
- 来源:
- Spitzer, R. L., Kroenke, K., & Williams, J. B. W. (1999). Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA, 282(18), 1737-1744.
参加基于此理论的经过验证的测试
阅读关於某个构念的资料能让您了解它是什麼,而经验证的测验工具则能让您了解自己在其中的位置。免费作答,幾分鐘內即可獲得结果。
证据概览
- 实证支持
- 强证据支持
- 重复验证
- 已充分重复验证
- 跨文化性
- 大致具普遍性
- 綜合分析(统合分析)
- 已收录 30 项
这些评等总结了关於该理論已发表的文獻,而非以此理論建构的任何单一测验的品质。它们是根据下方所列来源所作的編輯判斷,並會隨著证据累积而變化。
历史背景
PRIME-MD, published by Spitzer and colleagues in 1994, was a clinician-administered instrument designed to bring structured psychiatric assessment into general practice, but it took too long for routine use. The 1999 self-administered Patient Health Questionnaire was the response, and Kroenke, Spitzer and Williams's 2001 validation of the PHQ-9 made it the most widely used depression screen in the world. Its adoption was accelerated by being free of licensing cost, and it now anchors measurement-based care and collaborative-care models in many health systems.
构念
Depression Severity
As operationalized in the PHQ-9 and PHQ-2 (Kroenke, Spitzer & Williams, 2001), depression severity is assessed by the frequency of the nine cardinal symptoms of Major Depressive Disorder specified in DSM-IV: anhedonia, depressed mood, sleep disturbance, fatigue, appetite change, guilt/worthlessness, concentration difficulty, psychomotor change, and suicidal ideation. Scores index symptom burden rather than categorical diagnosis.
Generalized Anxiety Severity
As operationalized in the GAD-7 (Spitzer, Kroenke, Williams & Löwe, 2006), anxiety severity is assessed by the frequency of seven core symptoms of Generalized Anxiety Disorder specified in DSM-IV: nervousness, uncontrollable worry, excessive worry, restlessness, difficulty relaxing, irritability, and fearfulness.
Somatic Symptom Severity
As operationalized in the PHQ-15 (Kroenke, Spitzer & Williams, 2002), somatic symptom severity is assessed by the frequency and bothersomeness of 15 common physical symptoms (headaches, pain, gastrointestinal, cardiovascular, etc.) that account for more than half of all outpatient visits and are often associated with functional impairment.
工具
- Patient Health Questionnaire — 9 item(PHQ-9)Kroenke, K., Spitzer, R. L., & Williams, J. B. W.2001
- Patient Health Questionnaire — 15 item (Somatic Symptom Severity)(PHQ-15)Kroenke, K., Spitzer, R. L., & Williams, J. B. W.2002
- Patient Health Questionnaire — 2 item(PHQ-2)Kroenke, K., Spitzer, R. L., & Williams, J. B. W.2003
- Generalized Anxiety Disorder 7-item scale(GAD-7)Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B.2006
基于此理论的测试
PHQ-9: Patient Health Questionnaire (Depression)
9-item depression severity screener based on DSM criteria.
了解更多 →PHQ-2: Ultra-Brief Depression Screener
Ultra-brief 2-item depression screening for depressed mood and anhedonia.
了解更多 →GAD-7: Generalized Anxiety Disorder Scale
7-item anxiety severity screener for generalized anxiety disorder.
了解更多 →PHQ-15: Somatic Symptom Severity Scale
15-item somatic symptom severity screening for physical complaints linked to distress.
了解更多 →实际应用
The PHQ-9 is used for depression screening in primary care, for severity grading, and for tracking response to treatment over time, which is its most valuable and least appreciated function. The PHQ-2 serves as a first-stage filter in high-volume settings. Score bands map to severity categories that inform stepped-care decisions. Outside clinical settings, the appropriate use is entirely self-referential: a score indicates whether a conversation with a clinician is warranted, and carries no diagnostic meaning on its own.
如何测量
Self-administered symptom-frequency items over a two-week window, summed to a total with published severity bands; sensitivity and specificity are cutoff-dependent and population-dependent.
批评与局限
The conventional cutoff of 10 was derived in populations with relatively high depression prevalence; applied for universal screening in low-prevalence settings, it produces a majority of false positives, which is the core of the argument against untargeted screening. Levis and colleagues' individual-participant meta-analysis showed that cutoff-based estimates in the literature had been systematically inflated by selective reporting. Somatic items overlap with physical illness, inflating scores in medically ill populations. The PHQ-9 also compresses nine heterogeneous symptoms into one number, so identical totals can describe very different clinical pictures.
重要文献
- Spitzer, R. L., Kroenke, K. & Williams, J. B. W.. (1999). Validation and utility of a self-report version of PRIME-MD: The PHQ Primary Care Study. 10.1001/jama.282.18.1737
- Kroenke, K., Spitzer, R. L. & Williams, J. B. W.. (2001). The PHQ-9: Validity of a brief depression severity measure. 10.1046/j.1525-1497.2001.016009606.x
- Levis, B., Benedetti, A. & Thombs, B. D.. (2019). Accuracy of the PHQ-9 for screening to detect major depression: Individual participant data meta-analysis. 10.1136/bmj.l1476